August 12, 2019 (BOSTON) PR NEWSWIRE – binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®. The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.
Symetrica have been announced as the winner of the Venture Category at the British Private Equity & Venture Capital Association’s (BVCA) South West Management Team Awards 2017. Now in their ninth year, the BVCA Management Team Awards recognise and reward brilliant businesses up and down the country that are backed by UK private equity and venture capital investors.
The BVCA’s judges’ commented: “Symetrica has been a pioneer in its radiation detection technology and now has a leading position in homeland security. The judges were impressed with the way Heddwyn Davies had grasped this opportunity in 2016, driving a fourfold increase in sales, notably breaking into the US market, while at the same time bringing out a handheld version of the technology.”
Symetrica will now go forward into the national final to compete against the other UK regions before the national winners are announced at the BVCA Gala Dinner on 30 November in London.
Approval of Chlamydia test for marketing and sale in Europe
Atlas Genetics Ltd, the Bath, UK based, ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company’s io® platform. By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.
The launch of the io® CT test signals a new era in ultra-rapid molecular diagnostics. This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes. With the speed and accuracy of the io® CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality.
Object Matrix, the trusted storage partner to the media and entertainment industries, today announces that Sky, Europe’s leading entertainment company with over 21 million customers, has integrated MatrixStore object storage into Avid Interplay production workflows at its headquarters in London.
Sky is Europe’s leading investor in television content, with a combined programming budget of £4.9bn, commissioning its own original programming and entering into strategic partnerships to deliver the best possible TV viewing experience for customers. With production infrastructure often used to capacity, the Sky production team looked to find a solution that could not only scale into future workflows but also take the strain off the editing storage with seamless integration into current workflows.
Symetrica’s Radiation Detection and Identification Technology to be deployed by US Department of Homeland Security
Symetrica has announced that its patented radiation detection and identification technology will be deployed in the latest Handheld Radioisotope Identification Devices (RIIDs) that Smiths Detection Inc. has agreed to supply to the U.S. as part of a contract with the Department of Homeland Security (DHS). Symetrica’s Discovery Technology is at the heart of the Smiths Detection RadSeeker handheld radiation detectors for which the DHS Domestic Nuclear Detection Office (DNDO) recently awarded an IDIQ (indefinite delivery/indefinite quantity) contract with a maximum value of $143 million for the technology, its maintenance and associated training.
Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.
Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014. He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.
Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.
David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor. (more…)
Micrima, the Bristol company developing a safe, low-cost way of improving breast cancer detection, has gained CE marking for its MARIA (Multistatic Array processing for Radiowave Image Acquisition) product, paving the way for further supportive clinical trials in the UK and expansion into Europe. (more…)
Funds to accelerate global launch of Atlas io® molecular testing system
Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures and Technology Venture Partners. This newly announced financing follows on from the previously announced Series B fundraising of $25 million. (more…)
The Bristol team of YFM Equity Partners have taken over managing the South West Ventures Fund through a newly formed independent venture capital fund manager, Technology Venture Partners.
The South West Ventures Fund was established as one of the UK’s nine Regional Venture Capital Funds to invest up to £2m of risk capital into high growth small businesses. The fund is now fully invested and the portfolio includes Dynmark, a cloud based mobile intelligence and messaging platform and Micrima, which has developed innovative technology for breast cancer screening based on radiowaves instead of X-rays.
The spin-out will see the South West Ventures Fund continue to be managed by the three founding partners of Technology Venture Partners, Peter Davies, Nick Simmonds and Julian Dennard. Technology Venture Partners will focus on investing in emerging UK technology companies.